Penn Mutual Asset Management - HALOZYME THERAPEUTICS INC ownership

Quarter-by-quarter ownership
Penn Mutual Asset Management ownership history of HALOZYME THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$1,312,109
+1.5%
1,555,0000.0%1.23%
+5.5%
Q2 2023$1,292,816
-1.9%
1,555,0000.0%1.17%
-6.8%
Q1 2023$1,318,197
+4.3%
1,555,000
+19.2%
1.25%
-11.3%
Q4 2022$1,263,403
+14.3%
1,305,0000.0%1.41%
-2.5%
Q3 2022$1,105,000
-4.1%
1,305,0000.0%1.45%
-6.9%
Q2 2022$1,152,000
+1.3%
1,305,0000.0%1.55%
+17.7%
Q1 2022$1,137,0001,305,0001.32%
Other shareholders
HALOZYME THERAPEUTICS INC shareholders Q4 2023
NameSharesValueWeighting ↓
Wellesley Asset Management 128,679,626$110,468,0065.49%
CAMDEN ASSET MANAGEMENT L P /CA 77,223,000$65,160,7672.42%
Penn Mutual Asset Management 1,555,000$1,312,1091.23%
ZAZOVE ASSOCIATES LLC 9,108,000$7,715,0000.80%
DAVIDSON KEMPNER CAPITAL MANAGEMENT LP 50,000,000$42,190,0000.67%
LAFFER TENGLER INVESTMENTS, INC. 2,399$2,032,8230.60%
SHENKMAN CAPITAL MANAGEMENT INC 9,019,000$7,767,6720.58%
LINDEN ADVISORS LP 62,930,000$53,329,4250.55%
SSI INVESTMENT MANAGEMENT LLC 4,577,000$3,862,0740.32%
Sonora Investment Management Group, LLC 4,355,000$3,675,0600.31%
View complete list of HALOZYME THERAPEUTICS INC shareholders